Download PDF

1. Company Snapshot

1.a. Company Description

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases.It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications.The company has a license and collaboration agreement with Janssen Biotech, Inc.


Protagonist Therapeutics, Inc.was incorporated in 2006 and is headquartered in Newark, California.

Show Full description

1.b. Last Insights on PTGX

Protagonist Therapeutics' recent performance was driven by the FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis, unlocking $50 million in milestone payments and up to $580 million in future milestones. The company's partnership with Johnson & Johnson and ICOTYDE's best-in-class oral efficacy and safety profile are key growth drivers. Analysts have a "Moderate Buy" consensus rating, with 11 buy ratings and 2 hold ratings (Marketbeat). The company's pipeline, leveraging its Vectrix platform, targets obesity, hematology, and inflammation.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update

May -05

Source: accessnewswire.com

Card image cap

Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

Apr -28

Source: accessnewswire.com

Card image cap

Protagonist Therapeutics Reports Granting of Inducement Awards

Apr -16

Source: accessnewswire.com

Card image cap

SG Americas Securities LLC Sells 21,249 Shares of Protagonist Therapeutics, Inc. $PTGX

Apr -06

Source: defenseworld.net

Card image cap

Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Mar -28

Source: accessnewswire.com

Card image cap

Protagonist Partners With Johnson & Johnson To Compete With AbbVie's Skyrizi

Mar -24

Source: seekingalpha.com

Card image cap

Protagonist Therapeutics Soars as FDA Approves ICOTYDE for Plaque Psoriasis, Triggers $50M Milestone

Mar -23

Source: defenseworld.net

Card image cap

Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's Why

Mar -20

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.97%)

6. Segments

Peptide-based Therapeutics

Expected Growth: 8.97%

Protagonist Therapeutics' peptide-based therapeutics growth is driven by increasing demand for targeted therapies, rising prevalence of chronic diseases, and advancements in peptide engineering. The company's proprietary technology enables development of novel, orally stable peptides, addressing unmet needs in inflammatory bowel disease and other indications, fueling growth.

7. Detailed Products

PTG-300

PTG-300 is a hepcidin mimetic peptide and a potential treatment for beta-thalassemia and myelodysplastic syndrome.

PTG-200

PTG-200 is a injectable hepcidin mimetic peptide and a potential treatment for hereditary hemochromatosis.

PTG-400

PTG-400 is an oral hepcidin mimetic and a potential treatment for iron deficiency anemia.

8. Protagonist Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Protagonist Therapeutics, Inc. is medium due to the presence of alternative treatments and therapies for cancer and rare genetic disorders.

Bargaining Power Of Customers

The bargaining power of customers for Protagonist Therapeutics, Inc. is low due to the lack of negotiating power of individual patients and the high demand for innovative treatments.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Protagonist Therapeutics, Inc. is medium due to the presence of multiple suppliers for raw materials and equipment, but the high cost of switching suppliers.

Threat Of New Entrants

The threat of new entrants for Protagonist Therapeutics, Inc. is high due to the increasing interest in biotechnology and the availability of funding for startups.

Intensity Of Rivalry

The intensity of rivalry for Protagonist Therapeutics, Inc. is high due to the presence of established competitors and the high stakes in the biotechnology industry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 0.34%
Debt Cost 3.95%
Equity Weight 99.66%
Equity Cost 14.30%
WACC 14.26%
Leverage 0.34%

11. Quality Control: Protagonist Therapeutics, Inc. passed 7 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Protagonist Therapeutics

A-Score: 4.9/10

Value: 0.2

Growth: 9.4

Quality: 7.9

Yield: 0.0

Momentum: 9.5

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Praxis Precision Medicines

A-Score: 4.7/10

Value: 6.0

Growth: 7.9

Quality: 4.7

Yield: 0.0

Momentum: 9.5

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
ChromaDex

A-Score: 4.5/10

Value: 2.0

Growth: 7.3

Quality: 9.5

Yield: 0.0

Momentum: 7.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Immunome

A-Score: 4.3/10

Value: 6.2

Growth: 5.2

Quality: 4.7

Yield: 0.0

Momentum: 8.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
G1 Therapeutics

A-Score: 3.9/10

Value: 6.4

Growth: 6.6

Quality: 3.9

Yield: 0.0

Momentum: 6.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Y-mAbs Therapeutics

A-Score: 3.5/10

Value: 6.8

Growth: 7.2

Quality: 4.6

Yield: 0.0

Momentum: 1.5

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

99.21$

Current Price

99.21$

Potential

-0.00%

Expected Cash-Flows